In March 2013 it was reported by the World Health Organization (WHO) the first cases of human infections with avian influenza virus A (H7N9). From 2013 to December 2019 , 1568 cases have been reported with 616 deaths . H7N9 infection has been associated with high morbidity and mortality rates, and vaccination is currently the most effective way to prevent infections and consequently flu-related severe illness . Developing and producing vaccines against pandemic influenza viruses is the main strategy for a response to a possible pandemic . This study aims to present the production of three industrial lots under current Good Manufacturing Practices (cGMP) of the active antigen used to produce the pandemic influenza vaccine candidate against A (H7N9). These batches were characterized and evaluated for quality standards and tested for immunogenicity in mice . The average yield was 173.50 ± 7.88 µg/mL of hemagglutinin and all the preparations met all the required specifications . The formulated H7N9 vaccine is poorly immunogenic and needs to be adjuvanted with an oil in water emulsion adjuvant (IB160) to achieve a best immune response, in a prime and in a boost scheme . These data are important for initial production planning and preparedness in the case of a H7N9 pandemic.